Elpis Medicine Presents Promising Phase I Data for First-in-Class ES014 Monotherapy at ESMO Asia

Stock News12-05

On December 5, 2025, Elpis Medicine unveiled Phase I clinical trial results for its self-developed bispecific antibody ES014 through an oral presentation at the European Society for Medical Oncology Asia Congress (ESMO Asia). ES014, a first-in-class CD39/TGFβ bispecific antibody and the first globally to enter clinical trials, demonstrated preliminary yet clinically meaningful antitumor activity across multiple tumor types with high unmet medical needs.

Key findings include: - A 40% objective response rate (ORR) and 100% disease control rate (DCR) in desmoid tumors (DT), highlighting its potential as an innovative therapeutic option. - Preliminary efficacy in CD39-high non-small cell lung cancer (NSCLC) patients, laying the groundwork for precision treatment strategies. - Notably, ES014 may offer a novel therapeutic approach for wild-type gastrointestinal stromal tumor (GIST) patients with limited clinical options.

With core pipelines like ES014 showing early clinical benefits and the establishment of its globally rare Myeloid Cell Engager (MCE) platform, Elpis Medicine—a company dedicated to immunology and pioneering innovation—is poised for increasing value realization. Its potential for international licensing and partnerships is expected to grow.

From a long-term industry perspective, once the clinical value of innovative pipelines gains global recognition, sustainable cash flow may shift from "funding-driven" to "transaction and collaboration-driven."

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1144265289?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-05 15:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1144265289","market":"sh","top_or_hot":-1,"title":"Elpis Medicine Presents Promising Phase I Data for First-in-Class ES014 Monotherapy at ESMO Asia","media":"Stock News","content":"<p>On December 5, 2025, Elpis Medicine unveiled Phase I clinical trial results for its self-developed bispecific antibody ES014 through an oral presentation at the European Society for Medical Oncology Asia Congress (ESMO Asia). ES014, a first-in-class CD39/TGFβ bispecific antibody and the first globally to enter clinical trials, demonstrated preliminary yet clinically meaningful antitumor activity across multiple tumor types with high unmet medical needs.</p>\n<p>Key findings include:  \n- A 40% objective response rate (ORR) and 100% disease control rate (DCR) in desmoid tumors (DT), highlighting its potential as an innovative therapeutic option.  \n- Preliminary efficacy in CD39-high non-small cell lung cancer (NSCLC) patients, laying the groundwork for precision treatment strategies.  \n- Notably, ES014 may offer a novel therapeutic approach for wild-type gastrointestinal stromal tumor (GIST) patients with limited clinical options.</p>\n<p>With core pipelines like ES014 showing early clinical benefits and the establishment of its globally rare Myeloid Cell Engager (MCE) platform, Elpis Medicine—a company dedicated to immunology and pioneering innovation—is poised for increasing value realization. Its potential for international licensing and partnerships is expected to grow.</p>\n<p>From a long-term industry perspective, once the clinical value of innovative pipelines gains global recognition, sustainable cash flow may shift from \"funding-driven\" to \"transaction and collaboration-driven.\"</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Elpis Medicine Presents Promising Phase I Data for First-in-Class ES014 Monotherapy at ESMO Asia</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nElpis Medicine Presents Promising Phase I Data for First-in-Class ES014 Monotherapy at ESMO Asia\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-05 15:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>On December 5, 2025, Elpis Medicine unveiled Phase I clinical trial results for its self-developed bispecific antibody ES014 through an oral presentation at the European Society for Medical Oncology Asia Congress (ESMO Asia). ES014, a first-in-class CD39/TGFβ bispecific antibody and the first globally to enter clinical trials, demonstrated preliminary yet clinically meaningful antitumor activity across multiple tumor types with high unmet medical needs.</p>\n<p>Key findings include:  \n- A 40% objective response rate (ORR) and 100% disease control rate (DCR) in desmoid tumors (DT), highlighting its potential as an innovative therapeutic option.  \n- Preliminary efficacy in CD39-high non-small cell lung cancer (NSCLC) patients, laying the groundwork for precision treatment strategies.  \n- Notably, ES014 may offer a novel therapeutic approach for wild-type gastrointestinal stromal tumor (GIST) patients with limited clinical options.</p>\n<p>With core pipelines like ES014 showing early clinical benefits and the establishment of its globally rare Myeloid Cell Engager (MCE) platform, Elpis Medicine—a company dedicated to immunology and pioneering innovation—is poised for increasing value realization. Its potential for international licensing and partnerships is expected to grow.</p>\n<p>From a long-term industry perspective, once the clinical value of innovative pipelines gains global recognition, sustainable cash flow may shift from \"funding-driven\" to \"transaction and collaboration-driven.\"</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1574","symbol_name":"生物医药B类股","start_time":0,"source_url":"","article_id":"1144265289","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1144265289","pubTimestamp":1764919695,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"On December 5, 2025, Elpis Medicine unveiled Phase I clinical trial results for its self-developed bispecific antibody ES014 through an oral presentation at the European Society for Medical Oncology...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159938":"医药","BK1574":"生物医药B类股","09939":"开拓药业-B","BK1515":"抗疫概念","BK1161":"生物科技"},"translate_title":"Elpis Medicine在ESMO Asia上展示了一流ES014单药疗法的有希望的I期数据","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159938":1,"09939":1},"content_text":"On December 5, 2025, Elpis Medicine unveiled Phase I clinical trial results for its self-developed bispecific antibody ES014 through an oral presentation at the European Society for Medical Oncology Asia Congress (ESMO Asia). ES014, a first-in-class CD39/TGFβ bispecific antibody and the first globally to enter clinical trials, demonstrated preliminary yet clinically meaningful antitumor activity across multiple tumor types with high unmet medical needs.\nKey findings include:  \n- A 40% objective response rate (ORR) and 100% disease control rate (DCR) in desmoid tumors (DT), highlighting its potential as an innovative therapeutic option.  \n- Preliminary efficacy in CD39-high non-small cell lung cancer (NSCLC) patients, laying the groundwork for precision treatment strategies.  \n- Notably, ES014 may offer a novel therapeutic approach for wild-type gastrointestinal stromal tumor (GIST) patients with limited clinical options.\nWith core pipelines like ES014 showing early clinical benefits and the establishment of its globally rare Myeloid Cell Engager (MCE) platform, Elpis Medicine—a company dedicated to immunology and pioneering innovation—is poised for increasing value realization. Its potential for international licensing and partnerships is expected to grow.\nFrom a long-term industry perspective, once the clinical value of innovative pipelines gains global recognition, sustainable cash flow may shift from \"funding-driven\" to \"transaction and collaboration-driven.\"","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.10","shortVersion":"4.35.10","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1144265289","isCrawlerRequest":true}